title: Good response chemotherapy for late-recurring gastric cancer in the gluteals, with peritoneal and retroperitoneal dissemination.
abstract: A 64-year-old woman presented with advanced gastric cancer (signet ring cell carcinoma) and underwent total gastrectomy in 1996. Postoperative recovery was good, and she was monitored regularly on an outpatient basis. Abdominal computed tomography in 1999 revealed a soft tissue shadow ventral to the origin of the celiac artery. Careful monitoring was continued on an outpatient basis. The patient began to experience gluteal swelling and pain in April 2008. Symptoms rapidly exacerbated and the patient was hospitalized for further examination. Gluteal muscle biopsy revealed signet ring cell carcinoma and bilateral hydronephrosis. Gluteal recurrence of the original gastric cancer was suggested, and systemic chemotherapy consisting of S-1 at 100 mg/day (3 weeks on, 1 week off) and CDDP (day 8) was started. Following the 6th cycle of chemotherapy, gluteal symptoms disappeared and the patient was judged to have achieved clinical complete response (CR). No adverse events or image findings suggesting new recurrence have since been identified. The patient received a total CDDP dose of 585 mg and clinical CR has been maintained as of 14 years after total gastrectomy and 18 months after recurrence.
authors.affiliation: Department of Gastroenterology, Tokai University School of Medicine 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan. sakuma0922@yahoo.co.jp
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Sakuma
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Deguchi
authors.forename: Shinji
authors.initials: S
authors.lastname: Takashimizu
authors.forename: Fusao
authors.initials: F
authors.lastname: Ogasawara
authors.forename: Makoto
authors.initials: M
authors.lastname: Numata
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ohtani
authors.forename: Shinkichi
authors.initials: S
authors.lastname: Sato
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Mine
authors.forename: Yoshirou
authors.initials: Y
authors.lastname: Iwata
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002081:Buttocks; D018279:Carcinoma, Signet Ring Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D002945:Cisplatin / Q000008:administration & dosage; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008875:Middle Aged; D019042:Muscle Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D010094:Oxonic Acid / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D012074:Remission Induction; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin